Efficacy and Safety of Bodyweight-Adjusted Higher Dose of Ocrelizumab in Relapsing (MUSETTE) and Primary Progressive (GAVOTTE) Multiple Sclerosis

https://www.thelancet.com/infographics-do/musette-gavotte-graphical-abstract-26?dgcid=hubspot_email_infocusalerts-neurology_feature_lancetneuro26&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz--sD6cEE8wbxtYciMUDkVOnSbZft_x4ThKFFX7dETUNQ9txz1oQ6c2G6ozjT8dddmTpXI-yaqyqbthsWIMlU8wIBCFLHQ&_hsmi=421331774&utm_content=420563000&utm_source=hs_email